DOE Patents title logo U.S. Department of Energy
Office of Scientific and Technical Information

Title: TGF-.beta. antagonists as mitigators of radiation-induced tissue damage

Abstract

A method for treating tissue damage caused by radiation is described by use of a TGF-.beta. antagonist, such as an anti-TGF-.beta. antibody or a TGF-.beta. latency associated protein. It is administered not more than a week after exposure, and is particularly useful in mitigating the side effects of breast cancer therapy.

Inventors:
 [1]
  1. Oakland, CA
Issue Date:
Research Org.:
Lawrence Berkeley National Laboratory (LBNL), Berkeley, CA (United States)
OSTI Identifier:
870891
Patent Number(s):
5616561
Assignee:
Regents of University of California (Oakland, CA)
Patent Classifications (CPCs):
A - HUMAN NECESSITIES A61 - MEDICAL OR VETERINARY SCIENCE A61K - PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
C - CHEMISTRY C07 - ORGANIC CHEMISTRY C07K - PEPTIDES
DOE Contract Number:  
AC03-76SF00098
Resource Type:
Patent
Country of Publication:
United States
Language:
English
Subject:
tgf-; beta; antagonists; mitigators; radiation-induced; tissue; damage; method; treating; caused; radiation; described; antagonist; anti-tgf-; antibody; latency; associated; protein; administered; week; exposure; particularly; useful; mitigating; effects; breast; cancer; therapy; tissue damage; breast cancer; particularly useful; cancer therapy; damage caused; /514/

Citation Formats

Barcellos-Hoff, Mary H. TGF-.beta. antagonists as mitigators of radiation-induced tissue damage. United States: N. p., 1997. Web.
Barcellos-Hoff, Mary H. TGF-.beta. antagonists as mitigators of radiation-induced tissue damage. United States.
Barcellos-Hoff, Mary H. Wed . "TGF-.beta. antagonists as mitigators of radiation-induced tissue damage". United States. https://www.osti.gov/servlets/purl/870891.
@article{osti_870891,
title = {TGF-.beta. antagonists as mitigators of radiation-induced tissue damage},
author = {Barcellos-Hoff, Mary H},
abstractNote = {A method for treating tissue damage caused by radiation is described by use of a TGF-.beta. antagonist, such as an anti-TGF-.beta. antibody or a TGF-.beta. latency associated protein. It is administered not more than a week after exposure, and is particularly useful in mitigating the side effects of breast cancer therapy.},
doi = {},
journal = {},
number = ,
volume = ,
place = {United States},
year = {Wed Jan 01 00:00:00 EST 1997},
month = {Wed Jan 01 00:00:00 EST 1997}
}